KN060
Phase 2Small molecule
KN060 is one of 43 small molecule programs targeting Essential Hypertension. It is currently in Phase 2.
2
Indications
3
Total Trials
3
Active Trials
42
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
275 competitors in Total Knee Arthroplasty
#DrugCompanyPhaseTrials
1Cymbalta
Alnylam PharmaceuticalsPreclinical
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Xarelto
WWim Janssens
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Sufenta
LLeaf Vertical Inc.
Preclinical
EXPAREL
Pacira Pharmaceuticals, IncPreclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Nucynta
CCollegium Pharmaceutical, Inc.
Preclinical
KN060
SSuzhou Alphamab Co., Ltd.
Phase 2
Zanaflex
LLegacy Health System
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Total Knee Arthroplasty1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for KN060. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSuzhou Alphamab Co., Ltd.